Currently, Day One Biopharmaceuticals Inc [DAWN] is trading at $6.98, up 2.50%. An important factor to consider is whether the stock is rising or falling in short-term value. The DAWN shares have gain 11.68% over the last week, with a monthly amount glided 0.58%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Day One Biopharmaceuticals Inc [NASDAQ: DAWN] stock has seen the most recent analyst activity on August 19, 2025, when Piper Sandler initiated its Overweight rating and assigned the stock a price target of $25. Previously, Needham reaffirmed its Buy rating on October 09, 2024, and elevated its price target to $33. On August 01, 2024, upgrade upgraded it’s rating to Buy and revised its price target to $24 on the stock. Needham reiterated its Buy rating and increased its price target to $33 on April 24, 2024. BofA Securities downgraded its rating to a Underperform and reduced its price target to $9 on April 25, 2023. CapitalOne started tracking with a Overweight rating for this stock on February 08, 2023, and assigned it a price target of $40. In a note dated February 03, 2023, Oppenheimer initiated an Perform rating.
This stock has fluctuated between a low of $5.64 and a high of $16.76 over the last 52 weeks. Currently, Wall Street analysts expect the stock to reach $38.8 within the next 12 months. Day One Biopharmaceuticals Inc [NASDAQ: DAWN] shares were valued at $6.98 at the most recent close of the market. An investor can expect a potential return of 455.87% based on the average DAWN price forecast.
Analyzing the DAWN fundamentals
Trailing Twelve Months sales for Day One Biopharmaceuticals Inc [NASDAQ:DAWN] were 187.64M which represents 313.92% growth. Gross Profit Margin for this corporation currently stands at 0.94% with Operating Profit Margin at -0.6%, Pretax Profit Margin comes in at -0.48%, and Net Profit Margin reading is -0.51%. To continue investigating profitability, this company’s Return on Assets is posted at -0.18, Equity is -0.19 and Total Capital is -0.24. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 6.81 points at the first support level, and at 6.65 for the second support level. However, for the 1st resistance point, the stock is sitting at 7.07, and for the 2nd resistance point, it is at 7.17.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Day One Biopharmaceuticals Inc [NASDAQ:DAWN] is 9.65. On the other hand, the Quick Ratio is 9.53, and the Cash Ratio is 0.7. Considering the valuation of this stock, the price to sales ratio is 3.81, the price to book ratio is 1.55.
Transactions by insiders
Recent insider trading involved York Charles N II, COO and CFO, that happened on Aug 18 ’25 when 4106.0 shares were sold. Gen Counsel & Secretary, Dubow Adam completed a deal on Aug 18 ’25 to sell 4365.0 shares. Meanwhile, CHIEF EXECUTIVE OFFICER Bender Jeremy sold 16058.0 shares on Aug 18 ’25.
